Home/News/News details

Latest Clinical Trial determines that Vitamin D3 has no effect on Cancer risk

Apr 11, 2017

Latest Clinical Trial determines that Vitamin D3 has no effect on Cancer risk

A new clinical trial determines that elevated doses of vitamin D supplements might not lessen older women’s risk of developing cancer. In the United States, Cancer is the second most popular cause of death after heart disease and a greater load on the public health by accounting for nearly 600,000 deaths in the year 2014.

Several studies done in the past have hinted that vitamin D may aid in averting cancer. A few tests, for instance, have concluded that individuals with elevated levels of vitamins in the blood are less likely to acquire certain types of cancers, which included breast and colon cancers.

This disease is considered as a major public health concern, as nearly 40% of the United States populations are predicted to get a cancer diagnosis at some point of their lives. Moreover, the complete cost of the healthcare for cancer is estimated to reach $156 billion by the end of 2020.

The medical experiments done in the lab, vitamin D have also depicted certain activities which may dawdle the cancer growth – by boosting the elimination of abnormal cells. However, Dr. JoAnn Manson, of Brigham and Women's Hospital and Harvard Medical School in Boston explains that such studies do not necessarily prove that consuming vitamin D in reality leads to cancer risk to reduce.

Mansion stated that the clinical trials test vitamin D as compared to any inactive placebo. The new clinical trial however did not find and considerable benefit.

The trial included 2,303 postmenopausal women who were at random ascribed to consume either placebo pills or high doses of vitamin D3 (2000 IU) along with 1500 mg of calcium every day for four years. The trial included follow-up visits every six months.

The average age of these women was 65 and 99 percent were non-Hispanic Caucasian. The average serum 25-hydroxyvitamin D level was at 33ng/mL. This serum level rose to 43.9 ng/mL by 12 months and was thereafter maintained during the entire 4-year study. Whereas in the placebo group, the average serum level was kept at 31ng/mL throughout the study.

On the completion of the trial, 5.58% of women from placebo group and 3.89% of women who were in the vitamin D3 group were diagnosed with cancer. The vitamin D supplementation was not linked with lessened risk of developing cancer with a risk ratio of 0.70. The authors said that as compared with just below 6% in the placebo group – a variation which was not statistically substantial.

The concluding data from the clinical study proposes that calcium and vitamin D3 supplements do not lower cancer risk in older-postmenopausal women. Even though, the authors mentioned that “further research is necessary to assess the possible role of vitamin D in cancer prevention.”

The clinical trial was financed by the Creighton University and the U.S. National Cancer Institute.

footer pattern

All Copyrights reserve worldhealthcarenews.biz 2017.